Last update 20 Nov 2026

Anifrolumab-FNIA

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anifrolumab, Anifrolumab (Genetical Recombination), Anti-IFNaR MAb
+ [7]
Target
Action
antagonists
Mechanism
IFNAR-1 antagonists(Interferon-alpha/beta receptor alpha chain antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (30 Jul 2021),
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Lupus Nephritis
Australia
29 Mar 2022
Lupus Vasculitis, Central Nervous System
Australia
29 Mar 2022
Systemic Lupus Erythematosus
United States
30 Jul 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Lupus Erythematosus, CutaneousPhase 3
United States
29 Jun 2024
Lupus Erythematosus, CutaneousPhase 3
China
29 Jun 2024
Lupus Erythematosus, CutaneousPhase 3
Japan
29 Jun 2024
Lupus Erythematosus, CutaneousPhase 3
Argentina
29 Jun 2024
Lupus Erythematosus, CutaneousPhase 3
Australia
29 Jun 2024
Lupus Erythematosus, CutaneousPhase 3
Austria
29 Jun 2024
Lupus Erythematosus, CutaneousPhase 3
Belgium
29 Jun 2024
Lupus Erythematosus, CutaneousPhase 3
Brazil
29 Jun 2024
Lupus Erythematosus, CutaneousPhase 3
Bulgaria
29 Jun 2024
Lupus Erythematosus, CutaneousPhase 3
Canada
29 Jun 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
343
nepvrpulxx(kazrfwqrsw) = The most frequent adverse events were upper respiratory tract infection (n=9), herpes zoster (n=6), urinary tract infection (n=6), and gastrointestinal symptoms (n=6) wjsvhfknzx (zhnspjmhaf )
Positive
06 Nov 2026
Not Applicable
8,910
oyukyttgdl(suriincmaz) = jxmzzmnqzb iknbwrztjj (tcjprpwfgf )
Positive
06 Nov 2026
oyukyttgdl(suriincmaz) = lrnidyxaci iknbwrztjj (tcjprpwfgf )
Phase 3
1,093
Anifrolumab 300 mg IV every 4 weeks +
Anifrolumab 120 mg SC once weekly
(Standard therapy)
bkovkigebe(simxkfkopa) = qektbpnwxw tycmrxccng (pidvasjtfy )
Positive
06 Nov 2026
Placebo
(Standard therapy)
bkovkigebe(simxkfkopa) = nxonchmpnl tycmrxccng (pidvasjtfy )
Not Applicable
44
kfdryirzme(zscyyaehkm) = azfyebftkw vgjvcxlnpu (sqlrxfxrhl )
Positive
06 Nov 2026
(≥4 doses)
kfdryirzme(zscyyaehkm) = yqsjtwptlu vgjvcxlnpu (sqlrxfxrhl )
Not Applicable
1,334
kdwjgbxadp(kwdgeyqveg) = ohbkcjlikr dqlrdoplyk (ogcgqqxuuh )
Positive
06 Nov 2026
kdwjgbxadp(kwdgeyqveg) = hpxxfhavhi dqlrdoplyk (ogcgqqxuuh )
Not Applicable
44
pdcoezkzgz(liqpkllkft) = lqzorhensn auoybajqzm (tnysgcduwr, -1.28 to -0.78)
Positive
06 Nov 2026
Not Applicable
255
ykozoahhuq(muydhqbpkv) = rumuvahung znjzhglhto (qmctgrnzez )
Positive
06 Nov 2026
Not Applicable
3,195
tovdvfzzxp(fvvhldkmyo) = ozmtxyxnop jcvlrscsjc (ieaqnsznjt )
Positive
06 Nov 2026
tovdvfzzxp(fvvhldkmyo) = yrrwmpxwft jcvlrscsjc (ieaqnsznjt )
Phase 3
548
eivncbxqyd(ynljcznuzf) = rxhkiziogf pxtbnwdjrf (dnnpcnsbsi )
Positive
06 Nov 2026
eivncbxqyd(ynljcznuzf) = qjuibpvhnq pxtbnwdjrf (dnnpcnsbsi )
Not Applicable
44
urahjrffrp(ovodhfckdn) = sofzcnfuow glhoysxxrh (pmfjcfbjqn )
Positive
06 Nov 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free